$VRNA News
Last published 1y ago
- 1y agoMRKVRNAMerck Completes Acquisition of Verona PharmaBusiness WireAcquisition strengthens Merck's cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck (NYSE:MRK),
- 1y agoVRNAAcquisition of Verona by MSD Approved by the High Court of Justice of England and WalesGlobeNewswireLONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on
- 1y agoMRKVRNAShareholders of Verona Pharma Approve Proposed Acquisition by MerckGlobeNewswireLONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive
- 1y agoVRNAVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025GlobeNewswirePosters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc
- 1y agoMRKVRNAMerck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next DecadeBusiness WireAcquisition aligns with Merck's science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today Merck
- 1y agoVRNAVerona Pharma Announces June 2025 Investor Conference ParticipationGlobeNewswireLONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will participate in fireside chats at the following
- 1y agoVRNAVerona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025GlobeNewswireAnalyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc
- 1y agoVRNAVerona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireTotal net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding
- 1y agoVRNAVerona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31,
- 1y agoVRNAXERSXeris Announces Changes to Its Board of DirectorsBusiness WireXeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today
- 1y agoVRNAVerona Pharma Announces Amended Strategic Financing with Oaktree and OMERSGlobeNewswireRIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona
- 1y agoVRNAVerona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireOhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1
- 1y agoVRNAVerona Pharma Announces March 2025 Investor Conference ParticipationGlobeNewswireLONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following
- 1y agoVRNAVerona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the fourth quarter and full year
- 1y agoVRNAVerona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial HighlightsGlobeNewswireApproximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a
- 1y agoVRNAVerona Pharma Announces December 2024 Investor Conference ParticipationGlobeNewswireLONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following
- 2y agoAGENLGNDMRKTAK+3Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 GuidanceBusiness WireThird quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings
- 2y agoVRNAVerona Pharma to Present at Jefferies London Healthcare ConferenceGlobeNewswireLONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the Jefferies London
- 2y agoVRNAVerona Pharma plc (VRNA) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVRNAVerona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireOhtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad
- 2y agoVRNAVerona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the third quarter ended September
- 2y agoENTOOCSONCOVRNAVirometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the BoardBusiness WireVirometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today
- 2y agoVRNAVerona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024GlobeNewswireLONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces four oral presentations and two posters on analyses from its successful Phase 3
- 2y agoVRNARitedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*PR NewswireThe Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose ...
- 2y agoVRNAVerona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024GlobeNewswireOne oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona
- 2y agoVRNAVerona Pharma plc (VRNA) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVRNAVerona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireOhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH,
- 2y agoAGENAMGNCASILGND+8Ligand Reports Second Quarter 2024 Financial ResultsBusiness WireConference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast
- 2y agoVRNAVerona Pharma to Present at 44th Annual Canaccord Growth ConferenceGlobeNewswireLONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the 44th Annual
- 2y agoVRNAVerona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the second quarter ended June 30,
- 2y agoVRNAVerona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)GlobeNewswireOhtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call
- 2y agoVRNAVerona Pharma plc (VRNA) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVRNAVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswirePDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /
- 2y agoHTGCVRNAVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSGlobeNewswireNon-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona
- 2y agoVRNAVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024GlobeNewswirePDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and
- 2y agoVRNAVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31,
- 2y agoVRNAAndrew Fisher Joins Verona Pharma as General CounselGlobeNewswireLONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member
- 2y agoVRNAVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m. EST / 2:00
- 2y agoALDXLGNDMRKTVTX+2Ligand Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness WireConference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an
- 2y agoVRNAVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the fourth quarter and full year
- 2y agoVRNAMichael Austwick Joins Verona Pharma as Non-Executive DirectorGlobeNewswireLONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma") announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings
- 2y agoVRNAVerona Pharma to Present at 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireLONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces that senior management will present a company overview at the 42nd Annual J.P.
- 2y agoHTGCVRNAVerona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules CapitalGlobeNewswireLONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the "Company"), have entered into a debt
- 2y agoVRNAVerona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP AwardGlobeNewswireLONDON and RALEIGH, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces its President and CEO, David Zaccardelli, has won ‘Executive of the Year 2023'
- 3y agoAMGNANEBJAZZLGND+4Ligand Reports Third Quarter 2023 Financial ResultsBusiness WireRaising 2023 Guidance Investor and Analyst Day to be held on Tuesday December 12th in New York City Conference call begins at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today
- 3y agoVRNAVerona Pharma Announces November 2023 Investor Conference ParticipationGlobeNewswireLONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces that senior management will present a company overview at the following
- 3y agoVRNAVerona Pharma plc (VRNA) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoVRNAVerona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireUS FDA accepted NDA filing for ensifentrine for maintenance treatment of COPD PDUFA Target Action Date of June 26, 2024 Commercial launch preparations supported by strong balance sheet Conference call today at 9:00
- 3y agoVRNAVerona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateGlobeNewswireLONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that
- 3y agoVRNAVerona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023GlobeNewswireLONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), announces it will hold an Investor Update in New York City for investors and analysts on